V
Vifor Pharma AG
SIX:VIFN
Vifor Pharma AG
SIX:VIFN
Price:
166.15 CHF
0.48%
Market Closed
Updated:
May 2, 2024
Vifor Pharma AG
Cash from Financing Activities
|
Vifor Pharma AG
Cash from Financing Activities Peer Comparison
Comparables:
NOVN
NLSP
ROG
S
SDZ
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
V
|
Vifor Pharma AG
SIX:VIFN
|
Cash from Financing Activities
-CHf210.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
|
Novartis AG
SIX:NOVN
|
Cash from Financing Activities
-$14.3B
|
CAGR 3-Years
-86%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
-5%
|
|
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
Cash from Financing Activities
$17.4m
|
CAGR 3-Years
249%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Roche Holding AG
SIX:ROG
|
Cash from Financing Activities
-CHf4.2B
|
CAGR 3-Years
24%
|
CAGR 5-Years
17%
|
CAGR 10-Years
12%
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Cash from Financing Activities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Vifor Pharma AG's Cash from Financing Activities?
Cash from Financing Activities
-210.9m
CHF
-210.9m
CHF
Based on the financial report for Dec 31, 2021, Vifor Pharma AG's Cash from Financing Activities amounts to -210.9m CHF.
What is Vifor Pharma AG's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-1%
-1%
Over the last year, the Cash from Financing Activities growth was 21%.
You don't have any saved screeners yet
